{"name":"TCR2 Therapeutics","slug":"tcr2-therapeutics","ticker":"","exchange":"","domain":"","description":"TCR2 Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel T cell therapies for the treatment of solid tumors and hematologic malignancies. The company's lead product candidate, gavo-cel, is currently in Phase 1 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":98643000,"netIncome":-151822000,"cash":32746000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"gavo-cel","genericName":"gavo-cel","slug":"gavo-cel","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"gavo-cel","genericName":"gavo-cel","slug":"gavo-cel","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2023-09-06","type":"pipeline","source":"PR Newswire","summary":"Convergent Therapeutics Expands Leadership Team with the Appointments of Neil Bander, MD. as Chief Scientific Officer, Eric M. Sullivan as Chief Financial Officer, and Dimitris Voliotis, MD. as Senior","headline":"Convergent Therapeutics Expands Leadership Team with the Appointments of Neil Bander, MD. as Chief Scientific Officer, E","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFB4aFpRMS1mSW9VYzJRUlJCSWE5NTVENFl1V2NsSEo5U2xmalFHR2kwZjNWRnFST3FKQm92NGFpZFphRkdfUU9oTEFTRXFrZGR5OTFDVmgtUGZUSW94RlF3?oc=5","date":"2023-07-27","type":"trial","source":"Nature","summary":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results - Nature","headline":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim r","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNbzk4ZmxST2N2TXVwdmlkUE95ejdVbElSTlRid0lBR1Z6SU1la25vT2tHYmttbEhKenpGUHhjQURTOE10SkVQQlgyY1A0SzBrT0pRNi1TS0ZUbHRDNlFRTHE0clFGclRvV2N0OW1VX0JXanNiWUVJR0NsUVhqbjlETGp5VXl0RS13em00OWNmc3ZLamVYNWZfR3FnWkNJQzQ?oc=5","date":"2023-03-06","type":"deal","source":"BioPharma Dive","summary":"Adaptimmune acquires struggling cell therapy rival following layoffs - BioPharma Dive","headline":"Adaptimmune acquires struggling cell therapy rival following layoffs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPYURpUUhiTHF2VENwbWI1bVowSVh1Q0REUmVGOWRRVl9aNXJYa1ZiM3BERHhmZXgyamVmRnlLSzJXd3p2NmUyWFQtZ3h2RUtTWVNFTk42bVhEcU85bXczblNwREllOFlfM2dVY0x6YVNsZS1xUnVVM3ZLMVVLZ2dtRUVVNUlYdlhnbS1WekhpRWNwVFp2Y29tQnFXZmw5VUZtRkZhY1JSdEYzNnZZWHFKRHJ3?oc=5","date":"2023-03-06","type":"pipeline","source":"MedCity News","summary":"Adaptimmune, TCR2 Therapeutics to Combine in Marriage of Cell Therapy Developers - MedCity News","headline":"Adaptimmune, TCR2 Therapeutics to Combine in Marriage of Cell Therapy Developers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxQcnVIUlNSc05rZ1hURThNMGgzZEN4bUhHR1hPX0pzVXU2aFNXM2tKb2w5Rk04TXlNTVFteDl0dlVoVmMzR2tQTG5kZ0Q1cmRzdGt4U2FCR1h1NDdxVDJmM05sMm9KX2FlcmJ0TGJuQll5TWh4U0VkZEJiUldKSEJOaVhkelo5b2VVcW1XMEc4aDdCZ0FXb0dNWjdMSHp3Vm1tN2l3bG1fLWxGU3d3UWc?oc=5","date":"2023-03-06","type":"pipeline","source":"Fierce Biotech","summary":"Adaptimmune absorbs TCR² to extend cash runway and broaden T-cell pipeline - Fierce Biotech","headline":"Adaptimmune absorbs TCR² to extend cash runway and broaden T-cell pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNb0tZekZFWWlac1J6VXlDbGp1eHpFaVVyeEtEd1BFaGFNVDh6Tkx5c3EtdmpXQTQ4aWxIZW9GcHQ0OWRpTUNoRHhKTlp3VldvNWdZQUs3WHkxaTg1TE53dW5fUnVvd3ZiVjMxV2lHQ05KcVhQYVBpZWJpWE9jcFRBZ1hsX2ZHZFZvaFhwQkFvS000eW1ma3Jlc3VnZUVCVTd2bEp5LUhHaV80T3VDckZqdk5MUEtmUWZ3X3VPdTJtdw?oc=5","date":"2023-01-13","type":"pipeline","source":"Fierce Biotech","summary":"TCR² removed 20% of staff over summer, paving way for latest layoffs - Fierce Biotech","headline":"TCR² removed 20% of staff over summer, paving way for latest layoffs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOQkpLVWlYdlpwbWprUVA1X0xKajQ4Nk81UFhmaWFjb0Fib1BFc29lelpHTHFDYnU2Mm9UWnl1OTJQTXcxdGp2QUFyc252VFJ6bnROZmdnd0dQRzJPTVdRNmtsT185UkplN01rUkZ0a3NwdlA4NXkwZXdJOERXQXU0MEZTdk9YOFhvSDVmTFVkakFvUmdYM0MzcnBSNA?oc=5","date":"2023-01-06","type":"pipeline","source":"BioPharma Dive","summary":"Fate, two other cell therapy biotechs lay off staff, restructure research - BioPharma Dive","headline":"Fate, two other cell therapy biotechs lay off staff, restructure research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQbkVZU0kxYVlLUHdOemstZkg1WlZ3SkNSMXNiNEZPN1FxeVJPS29PdWV5ZUkzVEl5VERGYXhtSlBBYkNzV1ppcXIwdmhhVTEzanEtM0p6ZGJ0ZW1YbE5HVUo4OURMM0VoY056cWZ0T2RsMkxETFlnSk9GcTRCYXl3eUpsZElvbjBsY0EwOWFQcHJuSFZqbjd3ckdMQWowampfa2lHMUh1RlFGODhUZ004eWYwTEI5ZTJibFJjbWs2dHc1dk5qRnc?oc=5","date":"2023-01-05","type":"pipeline","source":"GlobeNewswire","summary":"TCR² Therapeutics Announces Pipeline Priorities for 2023 - GlobeNewswire","headline":"TCR² Therapeutics Announces Pipeline Priorities for 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNVTVKQ0hNSWNHQmJ5aGl3TmJmcWpBUlhXandtVzZPRjh5NDRYS2d1S3I4ajdBYUdHYnNlYUs4MERXemI5ZkVRak4xVjF2ZG9mMDhNU2NpY2pvcFlZWTRDd0lZOGg5M2RybUxtTW51RUFCWm4temVSYVdnZWxpckJyVC1ZZUg1T1RVT3pMMk5WZG1DdWkwTlIxQjRFWGtnUUNQNThVZjBwa014Z3k0UVFrMDEzaTRMNVI4OUFpTDRUbFBXUVBLS3c?oc=5","date":"2022-01-12","type":"regulatory","source":"citybiz","summary":"TCR² Therapeutics Appoints Rosemary Harrison as Chief Business and Strategy Officer - citybiz","headline":"TCR² Therapeutics Appoints Rosemary Harrison as Chief Business and Strategy Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNYThhY1ZIN2F0blhZR2pRX1RIZi10VGxzTW1zTjBXdGdSWVFMbFM0REJFZFBfWmU3aEZ0UkJ6ams4d2x2eHo0VW1xejNBZ2ZNU2dzZFJDdjNZenRXLWlXaUxNNUlhWjBNaVlaeDFNckg2ZzcybTg0cGo0N0l6bWNvR2JfVTJEOTJISUppZUxLd2JmbDRna3d3c1Q5ZXloUmN0eWVMSnh3SGZUUFhKR2pzdVZTa1NrSVVFMWFNZWl1dG1uLXBMYklLVmZTUE1DMUFNQmRqQzRoeTlrTDA?oc=5","date":"2021-12-01","type":"pipeline","source":"University of Utah Health","summary":"Sequencing of Bone Marrow DNA May Predict Leukemia Relapse After CAR-T Therapy | Huntsman Cancer Institute - University of Utah Health","headline":"Sequencing of Bone Marrow DNA May Predict Leukemia Relapse After CAR-T Therapy | Huntsman Cancer Institute","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQdVdrOEc4SWk4cDRDZUE1QkZ4cWxDcjZkU2Z3NmljN2FweWdSREMyTHpTUHFkdzRMMnpTTDl0RHhQS3NkRkxTckFyUTNZdDZtRWxlbUhJNFBrNlduMzd0NWo1UmtuOF9Rel9uZTZwTjhLNHF4b1k3eHUwSkxGUmJpamZEd0hocUd1VERUazZBTTlxOXktbGRrQlNsZTlId1JjTGpZQXBpRzFGMUw5V3JpcnlwMjBoVVd0V1hPN1J6TFZDUlU1anhiSm9Yc1Q?oc=5","date":"2020-10-25","type":"pipeline","source":"The ASCO Post","summary":"Activity of the KRAS G12C Inhibitor Sotorasib in KRAS G12C–Mutant Advanced Solid Tumors - The ASCO Post","headline":"Activity of the KRAS G12C Inhibitor Sotorasib in KRAS G12C–Mutant Advanced Solid Tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFBOcUVTYTVQRUxkLWdVSHUyN3VNelFRcjAxbGFQZVJVaUt2OUFCVnVwN0hnc1VaZjlwVGRmc0haZEg0clc2Q3ZOVmk2T005VlAyeXg3azZXd0p0MmxGcUh1cnJhdGZSTlFTc3gyYTYyR0dTY2hDRkg1N0pUdVVOeUU?oc=5","date":"2020-08-19","type":"pipeline","source":"marketscreener.com","summary":"TCR2 Therapeutics Inc. Stock (TCRR) - Quote Nasdaq - marketscreener.com","headline":"TCR2 Therapeutics Inc. Stock (TCRR) - Quote Nasdaq","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":98643000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-151822000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":32746000,"cashHistory":[],"totalAssets":208236000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}